D-enantiomeric Peptides for the Therapy of Chronic and Neuropathic Pain

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention introduces specific D-enantiomeric peptides (such as RD2 and D3, and their derivatives and homologs) designed for the treatment of chronic and neuropathic pain. These peptides specifically and selectively inhibit N-type neuronal calcium channels (NCC), which are key players in pain signaling. Unlike existing treatments like Ziconotide, these D-peptides offer the potential for easier (including oral) administration, greater stability in the body, reduced immune response, and a lower risk of severe side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of chronic pain, for instance in patients with cancer, AIDS, or other conditions resulting in persistent pain.
• Therapy for neuropathic pain arising from nerve injury or diseases affecting the nervous system.
• Replacement for current treatments (such as Ziconotide) where adverse effects or administration difficulties limit use.
• Development of new oral analgesic medications for severe pain.
• Formulation of pain relief drugs with improved safety and delivery profiles for long-term management.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly selective inhibition of N-type neuronal calcium channels, reducing unwanted side effects on other channel types.
• Oral bioavailability and longer half-lives due to the use of D-enantiomeric peptides, allowing for easier administration compared to current intrathecal drugs.
• Reduced risk of immune reactions and increased stability against enzymatic degradation in the body.
• Potential for reversible channel inhibition, improving safety and minimizing risks of permanent loss of pain sensation.
• Wider therapeutic range (higher IC50) allows for safer dosing, lowering risks of under- or overdosing.
• Improved patient comfort and compliance by eliminating the need for invasive administration methods (like spinal infusions).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and also polymers containing or consisting of RD2/D3 homologs having at least 50% identity and derivatives of RD2 and/or D3 for use as analgesic, for use in pain therapy, for use in the treatment of chronic and/or neuropathic pain and/or for the inhibition of N-type neuronal calcium channels (NCC).